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Pancreatic ductal adenocarcinoma (PDAC) features
a near-universal mutation in KRAS. Additionally, the
tumor suppressor PTEN is lost in 10% of patients,
and in mouse models, this dramatically accelerates
tumor progression. While oncogenic KRAS and
phosphatidylinositol 3-kinase (PI3K) cause divergent
metabolic phenotypes individually, how they syner-
gize to promote tumor metabolic alterations and
dependencies remains unknown. We show that
in KRAS-driven murine PDAC cells, loss of Pten
strongly enhances both mTOR signaling and macro-
pinocytosis. Protein scavenging alleviates sensitivity
to mTOR inhibition by rescuing AKT phosphorylation
at serine 473 and consequently cell proliferation.
Combined inhibition of mTOR and lysosomal pro-
cessing of internalized protein eliminates the
macropinocytosis-mediated resistance. Our results
indicate that mTORC2, rather than mTORC1, is an
important regulator of protein scavenging and that
protein-mediated resistance could explain the lack
of effectiveness of mTOR inhibitors in certain genetic
backgrounds. Concurrent inhibition of mTOR and
protein scavenging might be a valuable therapeutic
approach.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a very aggressive
type of cancer that, despite its fairly low incidence, is predicted
to be the second biggest contributor to cancer deaths by 2030
(Rahib et al., 2014). A near-universal oncogenic driver of PDAC
is the constitutive activation of the small GTPase protein
KRAS, most often caused by a mutation leading to an inability
to hydrolyze guanosine triphosphate (GTP). The resulting consti-
tutive induction of downstream signaling cascades leads to mul-
tiple changes that together facilitate rapid cell proliferation, and
this includes alterations in cellular metabolism (Bryant et al.,
2014). Previous work has shown that oncogenic RAS promotesCell Rep
This is an open access article undscavenging of multiple nutrient sources (Guo et al., 2011; Com-
misso et al., 2013; Kamphorst et al., 2013), which appears to be
distinct from oncogenic events leading to constitutive phospha-
tidylinositol 3-kinase (PI3K)-AKT activation, that promotes
de novo synthesis of cellular components from glucose and
free amino acids, particularly glutamine (Tong et al., 2009). The
metabolic scavenging phenotype, induced by KRAS in PDAC,
may be especially important for maintaining metabolic plasticity
and tumorigenesis in a tumor microenvironment that is poorly
vascularized and deprived of primary nutrients like glucose and
glutamine (Kamphorst et al., 2015).
One RAS-induced scavenging mechanism that has received
considerable attention is macropinocytosis (Commisso et al.,
2013). This is an endocytic process that cells use to internalize
extracellular material, including protein. After endocytosis, the
resulting vesicles, named macropinosomes, which contain the
internalized protein, fuse with lysosomes, leading to proteolytic
degradation. The freed amino acids generated by this process
support the metabolic needs of the cell (Michalopoulou et al.,
2016). Scavenging and subsequent hydrolysis of extracellular
protein via macropinocytosis was found to support proliferation
of KRAS-driven cells in medium devoid of essential amino acids
(EAAs) (Kamphorst et al., 2015; Palm et al., 2015). Importantly,
macropinocytosis was found to occur both in primary human
PDAC specimens (Kamphorst et al., 2015) and in in vivo mouse
models of PDAC (Davidson et al., 2017).
Although RAS is a main driver of macropinocytosis (Bar-Sagi
and Feramisco, 1986), other signaling events are also involved
in regulating various aspects of the macropinocytosis cascade.
For example, macropinosome formation is dependent on the
local production of phosphatidylinositol (3,4,5) triphosphate
(PIP3) lipids (Veltman et al., 2016). Consequently, PI3K, which
produces PIP3, and its negative regulator, PTEN, were found
to regulate lysosomal catabolism of scavenged proteins (Palm
et al., 2017). Interestingly, prostate tumor cells, deficient for
PTEN, survive the nutrient stress by internalizing necrotic bodies
through macropinocytosis (Kim et al., 2018). There is also an es-
tablished connection between PTEN and macropinocytosis
through the PI3K target mTORC1. Under nutrient-replete condi-
tions, mTORC1 promotes growth by inducing protein, nucleo-
tide, and fatty acid synthesis while suppressing catabolic pro-
cesses like autophagy (White and DiPaola, 2009; Howell et al.,
2013). In mouse embryonic fibroblasts (MEFs) harboring aorts 30, 2729–2742, February 25, 2020 ª 2020 The Author(s). 2729
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
KRAS-activating mutation, it was found that mTORC1 inhibited
catabolism of extracellular protein. Consequently, mTORC1 inhi-
bition induced albumin-facilitated proliferation during amino-
acid-depleted conditions (Palm et al., 2015). It was later
proposed, however, that this did not occur through release of
inhibition of lysosomal protein degradation but rather because
reduced mTORC1 signaling balances the demand of amino
acids required for protein synthesis with their supply via macro-
pinocytosis (Nofal et al., 2017). These recent findings may at
least partly explain why mTORC1-directed therapies are ineffec-
tive in PDAC (Wolpin et al., 2009; Javle et al., 2010).
Recent research shows that the other arm of the mTOR
pathway, mTORC2, is also important in PDAC progression (Dris-
coll et al., 2016). The mTORC2 complex regulates a wide range
of important cellular functions such as cell growth and survival,
metabolism, and actin cytoskeleton organization, mainly through
AKT phosphorylation at serine 473 that leads to activation of
downstream targets such as protein kinase C (PKC) and serum
and glucocorticoid-regulated kinase (SGK) (Cybulski and Hall,
2009). AKT can also be phosphorylated at threonine 308 by
another kinase, phosphoinositide-dependent kinase 1 (PDK1),
which leads to induction of mTORC1 signaling pathway. Full
activation of AKT requires phosphorylation of both serine 473
and threonine 308 (Vadlakonda et al., 2013). The induction of
different downstream signaling cascades indicates the different
cellular functions served by AKT. In human PDAC, AKT phos-
phorylation at serine 473 has been significantly associated with
poor survival (Kennedy et al., 2011). Importantly, a connection
between the mTORC2-AKT pathway and macropinocytosis
has thus far not been reported.
PTEN deficiency occurs in 10% of PDAC cases, on top of a
near-universalKRASmutation (Yingetal., 2011), and these tumors
arehighlyproliferative (Hill et al., 2010;Kennedyet al., 2011;Rose-
nfeldt et al., 2017). Here, we investigated how these oncogenic le-
sions synergized to inducemetabolic alterations in PDACcells us-
ing tumor cells derived from theKCPTEN (Krasactivation andPten
loss) genetically engineered mouse model of PDAC (Kennedy
et al., 2011; Morran et al., 2014). These cells proliferated more
rapidly than cells with wild-type Pten and were more sensitive to
mTOR inhibition. Pten loss also increased protein scavenging,
and this was mTORC2 rather than mTORC1 dependent. Surpris-
ingly, albumin supplementation rescued cell proliferation during
mTOR inhibition in these cells. Mechanistically, macropinocytosis
of albumin recovered AKT phosphorylation at serine 473 and
restored growth in an mTORC2 signaling-independent manner.
Combining mTOR inhibition with the lysosomal inhibitor chloro-
quine abrogated the rescue by albumin, leading to extensive cell
death. Combinatorial inhibition of mTORC2 and protein scav-
enging might be a good strategy for treating a subset of PDAC
tumors with activated KRAS and PTEN loss.
RESULTS
Pten Loss in KRAS-Driven PDAC Cells Accelerates
Proliferation and Causes Dependency on mTOR
Signaling
KRAS is nearly always mutated in PDAC, leading to its constitu-
tive activation (Hruban et al., 2000). In addition to KRAS, the tu-2730 Cell Reports 30, 2729–2742, February 25, 2020mor suppressor TP53 is mutated in 50%–70% of human PDAC
tumors (Scarpa et al., 1993). The effects of these genetic alter-
ations have been modeled in the Pdx1-Cre; KrasG12D/+;
Trp53R172H/+ (KPC) mouse model (Hingorani et al., 2005), which
has been found to recapitulate many of the salient features of hu-
man PDAC. More recently, it was found that 10%–15% of PDAC
patients display high mTOR phosphorylation (and hence activa-
tion) due to either loss of PTEN or activating mutations in the
PIK3CA gene (Scho¨nleben et al., 2006; Ying et al., 2011), and
this is associated with extremely poor prognosis (Garcia-Carra-
cedo et al., 2013). Importantly, Pten loss came up in two inde-
pendent studies where transposon-mediated mutagenesis
screens were carried out in PDAC mouse models to identify
novel partners of oncogenic RAS that accelerate tumor growth
(Mann et al., 2012; Pe´rez-Mancera et al., 2012). Also, Pdx1-
Cre; KrasG12D/+; Ptenflox/+ (KCPTEN) mice exhibit significantly
faster tumor progression than KPCmice (Hill et al., 2010; Morran
et al., 2014).
The fact that tumor progression is more rapid in KCPTENmice
than KPC mice indicated to us that the combination of mutant
Kras and Pten loss may induce metabolic alterations that facili-
tate rapid cell growth. In a variety of cell types, loss of the tumor
suppressor PTEN was found to cause constitutive activation
of the downstream PI3K pathway member AKT (Georgescu,
2010). Using KCPTEN cells, we confirmed an increase in phos-
phorylation of AKT and its immediate downstream target,
PRAS40 (Figure 1A). PRAS40 phosphorylation can be mediated
by either AKT or the mechanistic target of rapamycin complex 1
(mTORC1), leading to its dissociation frommTORC1, relieving its
inhibitory effect (Wiza et al., 2012). Consistent with that, we also
found increased levels of further downstream targets, p70S6K/
S6-RP, both of which are indicators of increased mTORC1 activ-
ity (Figure 1A). Therefore, mTOR is constitutively activated in
KCPTEN cells. Furthermore, to determine if increased prolifera-
tive capacity is maintained in culture, we compared cell prolifer-
ation rates of two KCPTEN cell lines with two KPC cell lines, with
each cell line derived from a different mouse (Figure 1B). These
results confirmed KCPTEN cell lines proliferate more rapidly
than cells with wild-type Pten.
mTOR is a key player in a large array of cellular processes,
including metabolism, survival, and proliferation, and has been
intensely investigated as a therapeutic target. mTOR integrates
signaling cues and nutrient availability to regulate growth (Lap-
lante and Sabatini, 2012). It has been found to induce anabolic
metabolism, including de novo synthesis of nucleotides, pro-
teins, and lipids. Indeed, we found that KCPTEN cells exhibit up-
regulated fatty acid biosynthesis (Figure S1A). Stemming from
this, we investigated whether the KCPTEN cells, due to the
constitutive mTOR signaling, would be sensitive to mTOR inhibi-
tion in conditions of differential nutrient availability. To test this,
we cultured both KPC and KCPTEN cells in standard Dulbecco’s
modified Eagle’s medium (DMEM) containing full amino acids
(completemedia) and treated the cells with themTORC1/2 inhib-
itors Torin1 or AZD2014, using concentrations that led to inhibi-
tion of mTOR signaling (Figure S1B). Proliferation was signifi-
cantly reduced in both cell types, although it was more
pronounced in KCPTEN cells (Figure 1C). We next assessed
the effect of mTOR inhibition in medium containing 5% of the
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Figure 1. KCPTEN Cells Are Exquisitely Sensitive to mTOR Inhibition
(A) Comparison of mTORC1 and AKT signaling in KPC and KCPTEN cells.
(B) Time-course proliferation assay of KPC and KCPTEN cells.
(C) Effect of dual mTOR inhibition (250 nM Torin1) on proliferation of KPC and KCPTEN cells. Cells were cultured in full DMEM with standard amino acid con-
centrations and treated with Torin1 for 72 h.
(D) As for (C), but with 5% of the standard DMEM essential amino acid (EAA) concentrations.
For (B)–(D), error bars represent SEM of three biological experiments, each conducted with three technical replicates. Significance was determined by one-way
ANOVA (B) or two-way ANOVA with Tukey corrections (C and D). ns, non-significant. ****p < 0.0001, ***p < 0.001, **p < 0.05, and *p < 0.01. Dashed lines indicate
the starting cell number.original EAA levels, including the well-known mTOR regulator
leucine (Lynch et al., 2000). While proliferation of KPC cells
was lower in these conditions than in complete medium, it wasnot further affected bymTOR inhibition. In contrast, the KCPTEN
cells remained exquisitely sensitive to mTOR inhibition despite
the low EAA levels (Figures 1D and S1C). Thus, Pten deficiency,Cell Reports 30, 2729–2742, February 25, 2020 2731
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Figure 2. PTEN Loss in KRAS-Driven PDAC Tumor Cells Upregulates Macropinocytosis
(A) Macropinocytosis assay using TMR-dextran as a marker of macropinosomes (red staining) in KPC and KCPTEN cells. Nuclei stained with DAPI (blue) (40,6-
diamidino-2-phenylindole) and Alexa 488 phalloidin (green) for actin staining (cellular periphery). The amiloride macropinocytosis inhibitor EIPA was used as a
control at 50 mM.
(B) Quantification of TMR-dextran fluorescence. An average of 30 z stack images was acquired per condition. Values were normalized to the average of the
vehicle-treated (DMSO) control.
(legend continued on next page)
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which is also known to activate several downstream pathways,
sensitizes to mTOR inhibition, regardless of free amino acid
availability.
Pten Loss in KRAS-Driven PDAC Tumor Cells Enhances
Macropinocytosis
Cells are able to take up amino acids in the free, monomeric,
form. Additionally, PDAC cells are able to acquire amino acids
through scavenging and subsequent hydrolysis of extracellular
protein (Commisso et al., 2013; Kamphorst et al., 2015). This oc-
curs via a process called macropinocytosis, which is induced by
oncogenic RAS (Commisso et al., 2013; Kamphorst et al., 2015).
The process of macropinocytosis has been studied in depth in
the model organism Dictyostelium discoideum (Dumontier
et al., 2000; Bloomfield et al., 2015), and multiple studies clearly
defined a role for PI3K and its product, PIP3, in macropinosome
formation (Veltman et al., 2016). Only recently, studies emerged
providing an initial link between the tumor suppressor PTEN and
protein scavenging in MEFs and prostate cancer cells (Palm
et al., 2017; Kim et al., 2018). Based on these observations, we
interrogated whether Pten loss, concurrent to causing constitu-
tive activation of anabolic mTOR signaling, could lead to
increased macropinocytosis in PDAC cells. We therefore used
the high-molecular-weight polysaccharide tetramethylrhod-
amine (TMR)-dextran, which represents an established marker
for active macropinocytosis (Commisso et al., 2014), to assess
the ability of both KPC and KCPTEN cells to take up extracellular
material. Although KPC cells displayed active macropinocytosis,
we observed that both KCPTEN cell lines had significantly higher
macropinocytic activity than KPC cells (Figures 2A, 2B, S2A, and
S2B), confirming the role of PTEN and consequently PI3K in
macropinocytosis. As expected, dextran uptake through macro-
pinocytosis was significantly inhibited in both KPC and KCPTEN
in the presence of the reportedly selective inhibitor of macropi-
nocytosis, ethylisopropyl amiloride (EIPA) (Figures 2A, 2B, S2A,
and S2B). We validated this further using cytochalasin D, which
is also known to block macropinocytosis (Mercer and Helenius,
2009; Recouvreux and Commisso, 2017) (Figure S2C). Following
ingestion, extracellular protein is hydrolyzed in the lysosomes,
generating free amino acids, which then feed into cellular meta-
bolic pathways. Thus, we tested if lysosomal protein hydrolysis
is also induced upon Pten loss. For this, we used fluorogenic de-
quenched bovine serum albumin (DQ-BSA), which self-
quenches when intact but starts to fluoresce upon lysosomal
digestion (Commisso et al., 2013). Using this assay on KPC
and KCPTEN cells (Frost et al., 2017), we observed that fluores-
cence was strongly increased in KCPTEN cells (Figures 2C, 2D,
S2D, and S2E). Thus, in the setting of Kras-driven PDAC cells,
PTEN deficiency increases protein scavenging and hydrolysis.
Protein Scavenging Is Regulated by mTORC2
Our results so far show that Pten deficiency leads to both
increased anabolic mTOR signaling and protein scavenging(C) Lysosomal processing of extracellular protein uptake via macropinocytosis w
(D) Quantification of DQ-BSA fluorescence. An average of 50 z stack images wer
For (B) and (D), error bar represents SEM of two biological experiments, each cond
was determined by one-way ANOVA. ns, non-significant. ****p < 0.0001 and ***pthrough macropinocytosis. Additionally, work by others showed
a direct link between mTOR and macropinocytosis (Palm et al.,
2015; Nofal et al., 2017). For these reasons, we next sought to
investigate the sensitivity of our PDAC cells to mTOR inhibition
in the absence or presence of extracellular bovine serum albu-
min (BSA). While KPC cells proliferate in low-EAA conditions,
mTOR inhibition had no further effect, nor did BSA supplementa-
tion (Figure 3A). This is different from previous work where it was
shown that Ras-driven MEFs do not proliferate under conditions
of deprived EAAs, a phenotype that can be rescued in the pres-
ence of extracellular protein (Palm et al., 2015; Nofal et al., 2017).
To determine if the observed difference between the two sys-
tems could be explained by the genetic diversity across the
different cell types, we cultured immortalized baby mouse kid-
ney cells (iBMK) harboring a Ras-activating mutation (Degen-
hardt et al., 2002; Degenhardt and White, 2006) and similarly
found they were still proliferating upon albumin supplementation
(Figure S3A). Increased TMR-dextran uptake was observed in
iBMK-RAS cells, confirming that oncogenic RAS inducesmacro-
pinocytosis (Figure S3B). Stemming from the above, we
conclude that the genetic background of cell lines can explain
differences in both resistance to amino acid deprivation and
the ability to proliferate with exogenous protein as an amino
acid source in certain conditions.
Next, we performed a head-to-head comparison of the ability
of KPC and KCPTEN cells to proliferate using protein in both low-
EAA and replete-medium conditions, in the presence or absence
of mTOR inhibition. We used cell number as a readout of prolif-
eration. Surprisingly, while mTOR inhibition and protein supple-
mentation had no effect on KPC cells in low EAA, in KCPTEN
cells, mTOR inhibition caused a growth defect, and this was
rescued by protein supplementation (Figure 3A). Furthermore,
we found that mTOR inhibition induced cell death via apoptosis,
as assessed by Annexin V staining, which was bypassed upon
albumin supplementation (Figure S3C). In replete-medium con-
ditions with full EAA, proliferation of KPC cells was significantly
affected bymTOR inhibition, but albumin did not rescue this (Fig-
ure 3B). In KCPTEN cells, however, the presence of albumin
again substantially rescued proliferation (Figures 3B and S3D).
Overall, this argues that macropinocytosis is a mechanism by
which KCPTEN cells overcome metabolic crisis and become
resistant to mTOR inhibition, independently of free amino acid
availability.
To investigate more in depth the role of Pten deficiency in
contributing to the obtained resistance against mTOR inhibitors,
we expressed human PTEN in KCPTEN1 cells (Figure 3C). We
found that KCPTEN cells expressing hPTEN were still sensitive
to mTORC1/2 inhibition, and protein supplementation could still
rescue the observed proliferation defects. However, the recov-
ery of proliferation in the presence of albumin was significantly
decreased in hPTEN-expressing cells compared to the empty
vector KCPTENs, indicating thatPten expression partially blocks
the proliferative advantage conferred by protein scavengingas assessed by DQ-BSA fluorescence.
e acquired per cell line. Values were normalized to the average value of KPC1.
ucted with three technical replicates. Scale bar represents 20 mm. Significance
< 0.001.
Cell Reports 30, 2729–2742, February 25, 2020 2733
Empty 
Vector
hPTEN
WT
KCPTEN1
Pten
β-tubulin
1 16
Rictor
β-tubulin
E. Vector RICTOR-KO 
pAKT (S473)
KCPTEN1
AKT
β-tubulin
1 0.1
1 0.2
A
B
C D
E F
G H I
(legend on next page)
2734 Cell Reports 30, 2729–2742, February 25, 2020
(Figure 3D). Indeed, PTEN expression significantly decreased
the uptake of extracellular material via macropinocytosis as as-
sessed by TMR-dextran (Figure S3G). Overall, our data suggest
that on top of the oncogenic KRas activation, Pten deficiency in-
creases macropinocytosis while its reexpression partially sup-
presses the ability to use extracellular protein to proliferate.
mTORC1 has been argued to regulate hydrolysis of scav-
enged protein (Palm et al., 2015), and more recently, it was
shown that (partial) mTORC1 inhibition balances amino acid de-
mand for growth with amino acid availability via macropinocyto-
sis (Palm et al., 2015; Nofal et al., 2017). Importantly, mTORC2 is
also known to play a significant role in PDAC (Driscoll et al.,
2016), but its exact role remains understudied. The mTOR inhib-
itors we used thus far (torin1 and AZD2014) are ATP-competitive
inhibitors of both mTORC1 and mTORC2. We therefore asked if
the induced cell death in KCPTEN cells was mTORC1 specific.
Rapamycin specifically blocks mTORC1 activity, but surpris-
ingly, there was no effect on proliferation of KCPTEN cells,
either in complete medium or in medium with low EAAs (Figures
S3E and S3F). This suggested that KCPTEN cells are dependent
on mTORC2 rather than mTORC1 signaling and that this
dependency can be overcome by macropinocytosis. To further
investigate the role of mTORC1, we asked if protein supplemen-
tation was able to re-engage mTORC1 downstream targets
(Figure S4A). Both Torin1 and AZD2014 were capable of
blocking mTOR activity, as evidenced by an abrogation of
phosphorylation of its downstream target, S6-RP. Furthermore,
phosphorylation of 4E-BP1, as indicated by the hyperphos-
phorylated isoforms b and g, was also blocked by the mTOR-
dual inhibitors (Figure S4A). Protein supplementation did not
rescue the phosphorylation of any of the mTORC1 targets,
providing further credence to the notion that the rescue
of impaired proliferation occurs independently of mTORC1.
Furthermore, using CRISPR/Cas9 technology, we created
mTORC1-deficient KCPTEN cells by ablating RAPTOR, which
is an essential subunit of the complex (Figure S4B). Confirming
our findings with mTORC1 inhibitors (rapamycin), RAPTOR-
knockout KCPTEN cells displayed no significant differences in
proliferation under low-EAA conditions (Figure S4C) or macropi-Figure 3. Protein Scavenging Is Regulated by mTORC2
(A) Effect of bovine serum albumin (BSA) supplementation (3%) on cell proliferation
(250 nM Torin1).
(B) As (A), but with standard DMEM amino acid concentrations.
(C) Pten protein levels in empty-vector- and hPTEN-expressing KCPTEN1 cells.
(D) Same as (A), but for hPTEN-expressing KCPTEN1 cells.
(E) RICTOR, pAKT serine 473, and total AKT protein levels in empty-vector- andRI
to b-tubulin and expressed relative to the empty vector. pAKT (serine 473) was n
(F) Cell number and apoptosis as readouts of proliferation and cell death, respec
(G) Quantification of TMR-dextran uptake and DQ-BSA fluorescence for RICTO
condition. Values were normalized to the empty-vector-expressing KCPTEN1.
(H) Same as (G), but for DQ-BSA fluorescence.
(I) Quantification of DQ-BSA fluorescence in KCPTEN1 E empty vector and RICTO
average of 45 z stack images were acquired per condition. Values were normaliz
For (A), (B), (D), (G), and (H), error bars represent SEM of three independent expe
Tukey-corrected two-way ANOVA. For (F) (cell number), error bars represent SEM
For (F) (apoptosis), error bars represent SEM of two biological experiments, each
Student’s t test with Welch’s corrections. For (I), error bars represent SEM of thre
was determined by one-way ANOVA with Tukey corrections. ns, nonsignificant. **
starting cell number.nocytosis levels (Figure S4D) compared to RAPTOR wildtype
cells. However, we observed increased lysosomal processing
measured by DQ-BSA fluorescence (Figure S4E), which has
also been reported by studies in RAPTOR-knockout MEFs
(Palm et al., 2015). Together, these findings indicate that the
observed proliferation mediated by protein scavenging is
mTORC1 independent.
Our results indicate that KCPTEN cells display sensitivity to
mTORC2 inhibition. To evaluate the role of mTORC2 we created
mTORC2-deficient KCPTENcells by silencing RICTOR, an essen-
tial subunit of mTORC2 (Figure 3E). We found that KCPTEN
RICTOR-knockout cells were somewhat more sensitive to the
low-EAA environment, and protein supplementation could not
rescue the observed proliferation defects (Figure 3F). RICTOR
deficiency also led to induction of apoptosis, which could not be
alleviated by protein supplementation either (Figure 3F). This
alignedwith our observation that uptake of TMR-dextran viamac-
ropinocytosis was significantly decreased (Figure 3G) and DQ-
BSA was completely abolished in RICTOR-knockout KCPTENs
compared to the empty vector (Figure 3H). These results implicate
a dominant role of mTORC2 in mediating protein scavenging.
Our experiments with inhibitors and genetic knockout both
demonstrate the involvement of mTORC2 in protein scavenging.
They also highlight a difference, with pharmacological inhibition
ofmTORC2 (Torin1) leading to defects in proliferation that can be
rescued by protein scavenging and CRISPR/Cas9-mediated
knockout blocking protein scavenging altogether. Genetic abla-
tion of RICTOR, in addition to blocking the kinase activity of
mTORC2 like the inhibitors, also disrupts the entire mTORC2
scaffold. To investigate more in depth the effect of the two
modes of mTORC2 disruption on protein scavenging, we utilized
the DQ-BSA assay and compared Torin1-treated KCPTEN cells
with RICTOR-knockout KCPTEN cells. Torin1 treatment did not
impair protein scavenging (DQ-BSA fluorescence), regardless
of protein supplementation. In RICTOR-deficient KCPTEN cells,
however, protein scavenging was abolished (Figure 3I). Overall,
these data clearly demonstrate an intricate interplay between
mTORC2 and protein scavenging that extends beyond its func-
tion as a kinase. In this regard, it is worth noting that mTORC2during Torin1 inhibition. Assay was done inmedia containing 5%EAAs for 72 h
CTOR-knockout (RICTOR-KO) KCPTEN1 cells. RICTOR levels were normalized
ormalized to total AKT levels and expressed relative to the empty vector.
tively, in RICTOR-KO KCPTEN1 cells cultured in 5% EAAs ±3% BSA for 72 h.
R-KO KCPTEN1 cells. An average of 60 z stack images were acquired per
R-KO cells. Empty vector cells were treated with Torin1 ±3%BSA for 24 ho. An
ed to the untreated (no BSA) empty-vector-expressing KCPTEN1.
riments, each with three technical replicates. Significance was determined by
of four biological experiments, each conducted with three technical replicates.
with three technical replicates. For (G) and (H), significance was determined by
e biological experiments, each with three technical replicates, and significance
**p < 0.0001, ***p < 0.0005 **p < 0.005, and *p < 0.01. Dashed lines indicate the
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has been shown to reside on endosomal vesicles (Ebner et al.,
2017).
Protein Scavenging Supports Proliferation through
Recovery of AKT Serine 473 Phosphorylation
As protein consumption supports proliferation of KCPTEN cells
despite inhibition of mTOR, we were interested in dissecting
the underlined molecular mechanisms of rescue of proliferation
by protein scavenging in these conditions. Autophagy is a well-
described catabolic mechanism often found upregulated in
RAS-driven tumors like PDAC. mTOR is a negative regulator of
autophagy (Rabinowitz and White, 2010). We therefore asked
whether autophagy induction contributes to the recovery of pro-
liferation in KCPTEN cells during mTOR inhibition. For this
reason, we utilized the CRISPR/Cas9 technology to create auto-
phagy-deficient KCPTEN cells by knocking out Atg7, which is an
essential component of autophagosomal membrane formation
(Figure S5A). We cultured the KCPTEN ATG7-knockout cells in
medium containing 5% EAAs and treated them with Torin1,
but proliferation was not affected in any of the two cell lines, sug-
gesting that autophagy does not contribute to the recovery of
proliferation (Figure S5B).
We next expanded our analysis of mTORC2-downstream
signaling mediators that could potentially explain the recovery
of proliferation. We noticed that while phosphorylation in serine
473 of the well-described mTORC2 target AKT was significantly
reducedwith themTORC1/2 inhibitors AZD2014 or Torin1, it was
restored upon protein supplementation regardless of free amino
acid availability (Figures 4A and 4B). We also investigated the ef-
fect on the other AKT phosphorylation site, threonine 308, which
was not greatly affected compared to the serine 473 site (Figures
4A and 4B). To determine whether the recovery of AKT serine
473 phosphorylation depends on macropinocytosis, we used
EIPA in combination with Torin1. Indeed, AKT phosphorylation
was significantly decreased upon inhibition ofmacropinocytosis,
demonstrating that AKT phosphorylation is macropinocytosis
dependent (Figure S5C). Furthermore, we showed that blocking
AKT significantly decreases TMR-dextran uptake via macropi-
nocytosis in KCPTEN cells (Figure S5D). While AKT is well known
to induce mTORC1 signaling and can promote cell proliferation
in this manner, it could also support proliferation via other
signaling cascades (Manning and Toker, 2017). To test if AKT
phosphorylation and hence activity upon protein supplementa-
tion is at least partially responsible for the rescue of proliferation,
we incubated the cells with either of two AKT inhibitors,
AZD5363 and AKT VIII, in addition to Torin1 and BSA (Figures
4C and S5E). Interestingly, when used in isolation, AZ5363,
which is an ATP-competitive inhibitor, had no effect on prolifer-
ation, while AKT VIII, an allosteric inhibitor, reduced proliferation,
indicating a mechanistic difference in the displayed suppression
profiles of the inhibitors. However, in both cases, BSA-mediated
restoration of cell proliferation of mTOR-inhibited cells was
greatly diminished with AKT inhibition, consistent with the notion
that restoration of AKT phosphorylation by protein supplementa-
tion is an important contributor to the observed rescue of cell
proliferation. Thus, protein scavenging restores growth in
mTOR-inhibited cells by reengaging AKT phosphorylation and
activity.2736 Cell Reports 30, 2729–2742, February 25, 2020To further investigate the role of AKT, we expressed myristoy-
lated AKT2 (myrAKT2) in KCPTEN1 cells (Figure S5F). myrAKT2-
expressing cells lack the pleckstrin homology (PH) domain
where PIP lipids bind, and it can therefore get phosphorylated
in a PIP-independent manner (Manning and Toker, 2017).
However, myrAKT2 can still be phosphorylated by mTORC2 at
its hydrophobic motif, which is intact. To check whether active
AKT could confer resistance to mTOR inhibitors, we treated
KCPTEN empty-vector- and myrAKT2-expressing cells with
Torin1 and supplemented with 3% albumin. We found that
KCPTEN1 myrAKT2 cells were still sensitive to mTOR inhibition
(Figure S5G). To further investigate this, we checked the effect
of mTOR dual inhibition and protein supplementation on AKT
phosphorylation levels. In myrAKT2-expressing KCPTEN cells,
Torin1 still blocked AKT phosphorylation at serine 473, which
was then recovered by protein supplementation similar to the
empty-vector-expressing KCPTEN cells (Figure S5H). Thus,
myrAKT2 is subject to the same phosphorylation events at the
hydrophobic domain, and hence activity regulation, as endoge-
nous AKT upon mTOR inhibition and protein supplementation,
lending further credence to our observations.
Combined mTOR and Lysosomal Inhibition Induce Cell
Death in KCPTEN Cells
Serine 473 of AKT is a known downstream phosphorylation
target of mTORC2 (Sarbassov et al., 2005). Our work shows
that this phosphorylation site of AKT is rescued by protein sup-
plementation during mTOR inhibition. The fact that mTORC2 ac-
tivity is also inhibited with the dual mTOR inhibitors suggests that
this phosphorylation event occurs through an alternative mech-
anism. Scavenging and recycling pathways that converge on the
lysosomal pathway have gathered a lot of attention and are
considered a hallmark of pancreatic cancer (Perera et al.,
2015; Pavlova and Thompson, 2016). Macropinosomes fuse
with lysosomes, and the extracellular protein they contain is hy-
drolyzed to yield free amino acids that feed into metabolic path-
ways (Michalopoulou et al., 2016). As protein supplementation
restores AKT phosphorylation in mTOR-inhibited cells, we
wondered if lysosomal processing of extracellular protein is a
critical event for AKT phosphorylation. We first confirmed that
the proteolytic degradation of extracellular protein is dependent
on lysosomes by using chloroquine, a lysosomal inhibitor. This
indeed abolished the lysosomal processing, as it is depicted
by the loss of DQ-BSA fluorescence in both KPC and KCPTEN
cell lines (Figures 5A, 5B, S6A, and S6B).
We next treated KCPTEN cells with both chloroquine and a dual
mTOR inhibitor. In the absence of the mTORC1/2 inhibitor Torin1,
chloroquine treatment did not affect AKT phosphorylation at
serine 473 (Figures 5C and S6C). However, in cells exposed to
supplemented protein, persistent AKT phosphorylation upon
mTOR inhibition was further abrogated with chloroquine treat-
ment (Figures 5C and S6C). In line with earlier obtained results
(Figure 4C), the loss of AKT phosphorylation, this time due to chlo-
roquine treatment, led to an inability of supplemented protein to
rescue mTOR-mediated inhibition of proliferation (Figures 5D
and S6D). We further validated these results by using another
lysosomal inhibitor, bafilomycin, that also abrogated proliferation
and AKT phosphorylation upon combination withmTOR inhibition
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and threonine 308) was normalized to the total AKT levels, and each value was expressed relative to the vehicle-treated (no BSA) control. Each blot is repre-
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(C) Effect of AKT inhibition on proliferation of KCPTEN cells. Cells were cultured in medium with 5% EAAs ±3% BSA, treated with the AKT inhibitor AZD5363
(1 mM) and/or Torin1 (250 nM) for 72 h. Values were normalized to the untreated (no BSA) control.
Error bars represent SEM of three biological experiments, each conducted with three technical replicates. Significance was determined by unpaired t test with
Welch’s correction. ***p < 0.0005 and **p < 0.001. Dashed lines indicate the starting cell number.(FiguresS6E andS6F). The abolished proliferationwas associated
with induction of cell death via apoptosis (Figure S6G). Thus, lyso-
somal hydrolysis of extracellular protein is critical for the extracel-
lular-protein-mediated resistance against mTOR inhibition.DISCUSSION
The continuous proliferation of cancer cells puts a high demand
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by upregulating de novo synthetic metabolic pathways (Elstrom
et al., 2004; Engelman et al., 2006) or, alternatively, by scav-
enging and reusing macromolecules (White, 2013). The latter
can be critical in a nutrient-restrictive tumor microenvironment,
such as in PDAC, where nutrient delivery is poor due to the
extensive fibrosis and deficient vasculature (Provenzano et al.,
2012; Chauhan et al., 2014; DelGiorno et al., 2014). The decision
to commit to de novo synthesis or scavenging appears to be, at
least in part, governed by oncogenic signaling (Pavlova and
Thompson, 2016). Constitutive activation of the PI3K-AKT-
mTOR pathway induces nucleotide and fatty acid synthesis, as
well as protein translation (Howell et al., 2013), whereas mutant
RAS induces both autophagy and macropinocytosis (Commisso
et al., 2013; Karsli-Uzunbas et al., 2014). Interestingly, in addition
to a near-universal KRASmutation, a significant portion of PDAC
tumors also feature loss of PTEN (Ying et al., 2011). This is asso-
ciated with a significantly reduced survival of patients, and
mouse models show that when combined, these oncogenic
events promote tumor progression (Garcia-Carracedo et al.,
2013). What metabolic program do these cells engage in? Our
data indicate that both mTOR-mediated anabolic metabolism
and macropinocytosis are upregulated in these cells. Critically,
our studies with mTOR inhibitors show that the cells can switch
between metabolic programs, and this is solely governed by the
availability of extracellular protein.
Others have previously established a link between mTOR,
specifically mTORC1, and protein scavenging. Palm et al.
showed that partial mTOR inhibition could increase cell prolifer-
ation in a low-free-EAA but protein-rich environment (Palm
et al., 2015). The authors proposed that mTORC1 inhibition
relieved its suppressing effect on lysosomal processing of
scavenged protein. This was later nuanced by Nofal et al.
(2017); it was shown that mTORC1’s regulation of lysosomal
processing was rather modest and that a more likely explana-
tion for the increased cell proliferation is that partial mTORC1
inhibition balances amino acid demand with supply through
macropinocytosis. Some of the results we obtained were subtly
different from the work published by these authors. For
example, our PDAC-derived KCPTEN cells were not sensitive
to a low-EAA environment (i.e., they did not die), as it was
observed for MEFs and iBMK cells (Figure S3A; Palm et al.,
2015; Nofal et al., 2017). Also, AKT inhibition had opposing ef-
fects to what was previously reported. This is most likely
caused by the specific cell types used and the genetic alter-
ations studied.Figure 5. Macropinocytosis Maintains AKT Phosphorylation, and Its A
(A) Lysosomal degradation of extracellular protein wasmeasured using DQ-BSA. K
4 h. Alexa 488-phalloidin (green) was used for F-actin and DAPI (blue) for nuclea
(B) Quantification of DQ-BSA fluorescence upon CQ treatment. An average of 5
vehicle-treated (DMSO) control.
(C) KCPTEN1 cells were cultured in medium containing 5% EAAs +3%BSA and tr
and threonine 308) was normalized to the total AKT protein levels and each va
lysosomal activity inhibits recovery of pAKT serine 473, bypassing the effect of p
(D) Combinatorial treatment with mTOR and lysosomal inhibition abolishes prolife
cells were left overnight to attach. Mediumwas then changed to 5%EAAs ±3%BS
Cell number was used as a readout.
For (B), error bars represent SEM of two independent experiments each condu
experiments, each conducted with three technical replicates. Significance was dApart from the above-mentioned subtle differences between
this and previous studies, we also encountered fundamentally
new observations with respect to the interaction between
mTOR and macropinocytosis. First, while both previous reports
focused on the interaction between mTORC1 and macropinocy-
tosis, our PDAC-derived cells appear to be mTORC2 rather than
mTORC1 driven; in contrast to dual mTOR inhibitors, rapamycin,
a mTORC1-specific inhibitor, does not substantially compro-
mise proliferation of KCPTEN (or KPC) cells (Figures S3E and
S3F), and hence, there was no proliferative rescue with protein
supplementation. Interestingly, rapamycin has been shown to
cause proliferative arrest in KCPTEN-bearing mice (Morran
et al., 2014). However, it has been shown that prolonged treat-
ment with rapamycin can also lead to mTORC2 inhibition (Sar-
bassov et al., 2006; Schreiber et al., 2015). We further validated
our results by genetically disrupting mTORC1 and mTORC2 via
RAPTOR and RICTOR knockout, respectively. Indeed, RAPTOR
ablation had no effect on proliferation ormacropinocytosis, while
it significantly increased lysosomal processing of extracellular
protein, as has also been shown by others (Figures S4C–S4E).
Interestingly, disruption of mTOR2 complex by knocking out
RICTOR abolished protein scavenging, which consequently led
to significantly compromised proliferation and induction of
apoptosis, which could no longer be recovered by protein
supplementation (Figures 3F–3H). The different outcomes of
the pharmacological inhibition and the genetic disruption of
mTORC2 indicate that beyond its kinase activity, the mTORC2
complex is a critical mediator macropinocytosis and lysosomal
functioning (Figure 6). The exact underlying mechanism will
be subject to future research. Overall, our data argue that
combining lysosomal inhibition with mTOR inhibitors is an effi-
cient therapeutic strategy against PTEN-loss-driven PDAC cells.
The second fundamentally novel observation we made was
that protein-mediated rescue of cell proliferation during mTOR
inhibition is not due to balancing amino acid supply and demand;
rather, it is due to recovery of AKT phosphorylation at serine 473,
which is a well-established direct phosphorylation target of
mTORC2 (Sarbassov et al., 2005). This at least partially leads
to recovery of proliferation, and it suggests that AKT contributes
to cell proliferation and hence events such as protein translation
independently of mTOR signaling (Figure 6).
How does macropinocytosis lead to recovery of AKT phos-
phorylation? Our experiments with the lysosomal inhibitor chlo-
roquine (Figure 5C) argue that hydrolysis of the extracellular
protein is a step of critical importance for this event to occur.brogation Restores Sensitivity to mTOR Inhibition
C-PTEN cells were treated with vehicle (DMSO) or chloroquine (CQ; 50 mM) for
r visualization. Scale bar represents 20 mm.
0 z stack images were acquired per condition. Values were normalized to the
eated with Torin1, CQ, and their combination for 24 and 48 h. pAKT (serine 473
lue was expressed relative to the vehicle-treated (no BSA) control. Blocking
rotein supplementation.
rative advantage conferred by protein. The same cell number was plated, and
A and cells treated with 30 mMCQ, 250 nM Torin1, or the combination for 72 h.
cted in triplicate wells. For (D), error bars represent SEM of three biological
etermined by two-way ANOVA. ****p < 0.0005, ***p < 0.0001, and **p < 0.001.
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Figure 6. Working Model
Pancreatic cancer cells with concurrent KRAS activation and PTEN loss up-
regulate the uptake of extracellular protein via macropinocytosis. Both PI3K
and AKT play an important role in the regulation of this mechanism. mTORC2
scaffold was found to regulate both uptake (macropinocytosis) and lysosomal
processing of scavenged extracellular proteins. Under mTOR-inhibited con-
ditions, lysosomal hydrolysis of extracellular protein leads to recovery of AKT
phosphorylation at the serine 473 site, which restores proliferation. Blocking
lysosomes with CQ inhibits degradation of scavenged protein and resensitizes
PDAC cells with concurrent KRAS activation and PTEN loss to mTOR
inhibition.From this, it is reasonable to propose that protein-derived amino
acids play an important role. It is interesting to note that we see
protein-mediated rescue of AKT phosphorylation also occurring
in high-free-amino-acid conditions. It may be that it is free amino
acid concentrations at certain locations in the cell (lysosome
versus cytoplasm) that mediate AKT phosphorylation. Alterna-
tively, lysosomal processing of extracellular proteins may acti-
vate, in a yet-unknown manner, kinases that would phosphory-
late and activate AKT serine 473 when mTORC2 is inhibited.
For example, it has been shown that integrin-linked kinase
(ILK) and DNA-activated protein kinase (DNA-PK) can bind and
phosphorylate the serine 473 site of AKT (Persad et al., 2000;
Feng et al., 2004). The exact link between lysosomal hydrolysis
and AKT phosphorylation is subject to further interrogation.
Inhibition of mTOR activity (particularly mTORC1) has
received significant attention as a therapeutic modality, but
clinical results, including in PDAC, have been disappointing
(Javle et al., 2010). The fact that mTOR inhibition can promote
tumor cell growth in a primary nutrient-poor, but protein-rich,
microenvironment has been put forward as an explanation for
the lack of clinical success. The results presented here demon-
strate that a combination of specific oncogenic alterations and
access to extracellular protein is enough to circumvent mTOR
inhibition. Protein scavenging is hence a bona fide resistance
mechanism. These results should be taken into consideration
when investigating the therapeutic effects of mTOR inhibition
in the future.
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ANTIBODIES
Rabbit Monoclonal anti-phosphoAKT (Ser473) Cell Signaling Technology Cat#4060S; RRID:AB_2315049
Rabbit Monoclonal anti-phosphoAKT (Thr308) Cell Signaling technology Cat#4056S; RRID:AB_331163
Rabbit Monoclonal anti-AKT Cell Signaling Technology Cat#4685S
Rabbit Monoclonal anti-P70SK Cell Signaling Technology Cat#2708S; RRID:AB_390722
Rabbit Monoclonal anti-phosphoP70SK (Thr389) Cell Signaling Technology Cat#9234S; RRID:AB_2269803
Rabbit Monoclonal anti-phosphoS6-RP (Ser235/236) Cell Signaling Technology Cat#4858S; RRID:AB_916156
Rabbit Monoclonal anti-S6-RP (5G10) Cell Signaling Technology Cat#2217S; RRID:AB_331355
Rabbit Monoclonal anti-phosphoPRAS40 (Thr246) (D4D2) Cell Signaling Technology Cat#13175S; RRID:AB_2798140
Rabbit Monoclonal anti-PRAS40 (D23C7) Cell Signaling Technology Cat#2691; RRID:AB_2225033
Rabbit anti-4EBP1 (53H11) Cell Signaling Technology Cat#9644S; RRID:AB_2097841
Rabbit Monoclonal anti-ATG7 Cell Signaling Technology Cat#8558S; RRID:AB_10831194
Rabbit Monoclonal anti-PTEN Cell Signaling Technology Cat#9559S; RRID:AB_390810
Mouse anti-RAPTOR (24C12) Cell Signaling Technology Cat#2280S; RRID:AB_561245
Mouse Polyclonal anti-RICTOR Cell Signaling Technology Cat#2140; RRID:AB_2179961
Mouse Monoclonal anti-phosphoAKT2 (Ser474) (D3H2) Cell Signaling Technology Cat#8599; RRID:AB_2630347
Mouse Monoclonal anti-AKT2 Cell Signaling Technology Cat#3063S; RRID:AB_2225186
Donkey anti-mouse IRDye 800CW Fisher Scientific Cat#926-32212; RRID:AB_621847
Goat anti-Rabbit, Alexa Fluor 488 Invitrogen Cat# A-11008; RRID:AB_143165
Mouse monoclonal anti-b tubulin Sigma Cat#T4026; RRID:AB_477577
CHEMICAL; PEPTIDES; AND RECOMBINANT PROTEINS
AKT-VIII, AKT inhibitor Cayman Chemicals CAY14870
AZ2014, mTORC1/2 inhibitor AstraZeneca N/A
AZ5363, AKT inhibitor AstraZeneca N/A
Chloroquine, lysosomal inhibitor Sigma C6628
EIPA, macropinocytosis inhibitor Sigma Ca#1154-25-2
Rapamycin, mTORC1 inhibitor Sigma Cat#53123-88-9
Torin1, mTORC1/2 inhibitor Tocris Bioscience Cat#4247
Cytochalasin D, macropinocytosis inhibitor Cayman Chemicals CAY11330
Bafilomycin A1, lysosomal inhibitor Tocris Bioscience Cat#1334
TMR-Dextran, macropinocytosis marker Thermo-Scientific Cat#D1818
DQ-BSA, macropinocytosis/lysosomal marker Molecular Probes D12051
Phalloidin conjugated to Alexa488 Thermo-Scientific Cat#A12397
Clarity Max ECL Bio-Rad 6305
SuperSignal West Femto Maximum Sensitivity Substrate Thermo Fisher Scientific 34096
Critical Commercial Assays
FITC-Annexin V, apoptosis marker Invitrogen V13242
EXPERIMENTAL MODELS: CELL LINES
Mouse Cell Lines: Pdx1-Cre; KrasG12D/+; Trp53R172H/+
for KPC1 (C57BL/6J) and KPC2 (mixed background) cell
lines
Dr. Jennifer Morton’s Laboratory N/A
Mouse Cell Lines: Pdx1-Cre; KrasG12D/+; Pten-flox for
KCPTEN1 and KCPTEN2 cell lines
Dr. Jennifer Morton’s Laboratory N/A
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OLIGONUCLEOTIDES
Primers for RICTOR: CACCGCCCGTCAATATGGC
GGCGAT
This paper N/A
Primers for RAPTORT: CACCGCGATCCGTGTCTA
CGACAGG
This paper N/A
Recombinant DNA
pLNCX1 MyrAKT2 Addgene #272894
pQCXIH hPTEN Dr David Bryan’t Laboratory N/A
Software and Algorithms
ImageJ Schneider et al., 2012 https://imagej.nih.gov/ij/
Graph Pad Prism 7 GraphPad Software https://www.graphpad.com/scientific-
software/prism/
Image Studio Lite Li-Cor Biosciences https://www.licor.com/bio/image-studio-lite/LEAD CONTACT AND MATERIALS AVAILABILITY
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Jurre
Kamphorst (jurre.kamphorst@glasgow.ac.uk).
This study did not generate new unique reagents.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines and cell culture conditions
Cell lines were originally derived from two separate Pdx1-Cre; KrasG12D/+; Trp53R172H/+ (KPC) mice (both females) (one with
mixed background (KPC2) and one with C57BL/6J (KPC1) or from two separate Pdx1-Cre; KrasG12D/+; Ptenflox/+ (KCPTEN) (fe-
males) mice. These cell lines were kindly provided by Dr Jennifer Morton’s lab and they have been authenticated. Cells were routinely
passaged in Dulbecco’s Modified Eagle Medium (DMEM, Sigma) with 25 mM glucose and 2 mM L-glutamine, supplemented with
10% (v/v) fetal bovine serum (FBS; Sigma), split at 80% confluence, and were routinely checked for mycoplasma. The cells were
incubated at 37C and 5% CO2.
METHOD DETAILS
Essential Amino Acid Starvation
For essential amino acid (EAA) starvation experiments, the same number of cells (25.000) was plated in full DMEM media and left
overnight to adhere. The following daymediumwas removed, and cells were rinsed oncewith PBS. Cells were then cultured in Earle’s
Balanced Salt Solution (EBSS) medium (Thermo Fisher Scientific) supplemented with 5% (1x) MEM Amino Acids and MEM Non-
Essential Amino Acids (Sigma), 100x Vitamins, 2 mM Glutamine, 4.5 mM Glucose (for a final concentration of 10mM), 10% dialyzed
FBS (Sigma) and 3% Bovine Serum Albumin (Sigma) for 72h unless indicated otherwise. The following inhibitors were added (along
with changing medium and left for 72hours) as indicated: 1 mM A2014, 200 nM AZD8186, 200 nM AZD8835, 1 mM AZD5363 (from
AstraZeneca); AKT VIII (CaymanChemical), 20 mM for TMR-Dextran uptake experiments and 10 mM for 72h proliferation assay); Chlo-
roquine (Sigma, 50 mM for DQ-BSA Assay and 15 mM for 72hour-proliferation Assay), 2 mMCytochalasin (Cayman Chemical), 50 nM
Rapamycin (Sigma); 250 nM Torin1 and 1nMBafilomycin (Tocris Bioscience). Cell number was used as a readout of proliferation and
it was determined using the CASY Cell Counter (Roche). 2.5x 104 RICTOR-KO and RAPTOR-KO KCPTEN cells were cultured in full
DMEM and left overnight to adhere to plastic. Themediumwas then changed to 5%Essential amino acid in the presence or absence
of 3%Bovine Serum Albumin (BSA) and left for 72 hours prior to cell number count by CASY Cell Counter (Roche) or subjected to the
Annexin V protocol as described below.
RICTOR and RAPTOR knock-out cell lines
For CRISPR/Cas9 genome editing of the ATG7, RAPTOR and RICTOR genes we used plasmids kindly provided by Kevin Ryan’s lab
(O’Prey et al., 2017). The v2.o plasmid (O’Prey et al., 2017) was used to clone guide sequences targeting Rictor: CACCGCCCGTCAA
TATGGCGGCGAT, and Raptor: CACCGCGATCCGTGTCTACGACAGG. Lentivirus was generated for each plasmid in HEK293T cells
and used to infect the relevant cell line. KCPTEN1 cell line was transfected with 5 mg control plasmid (empty vector) or 5 mg plasmid
containing either the Atg7, the Rictor or the Raptor sequence. After two rounds of transfection, cells were subjected to selection withe2 Cell Reports 30, 2729–2742.e1–e4, February 25, 2020
2 mg/ml puromycin for 7 days. Following puromycin selection, the ATG7, RICTOR and RAPTOR knock-out cell lines were confirmed
by assessment of Atg7, Rictor, Raptor, pAKT (S473)/total AKT and pP70-S6K/total P70-S6K protein levels via western blotting.
Retrovirus was produced in 4inx cells and used to infect the KCPTEN cells. 5 mg of pLNCX1 Myr-AKT2 plasmid (Addgene #27294)
was used to express myr-AKT2 to KCPTEN1 cells following the supplier’s protocol. After two rounds of transfection, cells were then
subjected to 200 mg/ml neomycin selection for 7 days. Similarly, for expression of human PTEN wild-type in KCPTEN1 cells, 5 mg of
the pQCXIH plasmid were used. KCPTEN1 cell line was transfected with pQCXIH control plasmid or wild-type hPTEN and after two
rounds of transfection it was subjected to 400 mg/ml hygromycin selection for 7 days. Overexpression was assessed by assessing the
protein levels of pAKT2 (S474)/total AKT and Pten via western blotting.
De novo fatty acid biosynthesis
Fatty acid labeling was performed as published previously (Tumanov et al., 2015). DMEM supplemented with 10mM U-13C-glucose
and 2mMU-13C-glutamine (sigma) and 10%dFBSwas used as indicated. After 72h incubation, cells were placed on ice andmedium
was aspirated, The cells were then washed 2x with ice-cold PBS, quenched with 0.75 mL of 1:1 v/v PBS:Methanol kept at 20C.
After cell scraping, the extraction solvent was transferred to glass tubes, and the total fatty acids was extracted in 0.5 mL chloroform
(kept20C) and dried under nitrogen gas. Lipids were saponified and methylated with toluene, methanol and methanolic-HCL, and
then vortexed and incubated at 100C for 60min. Fatty acid methyl esters were extracted with water and hexane and hexane fraction
analyzed by GC/MS (Tumanov et al., 2015). Fraction de novo synthesized equals 1-fraction M0.
Cell Death Assay (Flow Cytometry)
Apoptosis and necrosis were assayed by flow cytometry. 3x105 cells were seeded on six-well plates for treatment with mTOR/lyso-
somal inhibitors or 2.5x104 cells on 12-well plates for RAPTOR-KO and RICTOR-KO KCPTEN1 in full DMEMmedium and left O/N to
attach. Medium was then replaced with 5% EEAs and cells incubated with mTOR/CQ with or without 3% albumin for 72h. Medium
was collected, and cells were washed with PBS which was also collected. After trypsinization, cell suspension was added to the
collected medium. A suspension containing 105 cells was centrifuged at 2000 g for 5 min and supernatant removed. The pellet
was re-suspended with in 1X Annexin-binding buffer containing FITC-Annexin V (Apoptosis marker) (Invitrogen). Samples were
mixed gently for 15 min at room temperature. Finally, 100 mg/mL of Propidium Iodide (PI-necrosis marker) were added to the solution
and samples were processed in Attune NxT Flow Cytometer (Invitrogen).
TMR-Dextran and DQ-BSA Assays
TMR-Dextran Assay
Cells were seeded on glass coverslips in full DMEM for 24h. Cells were then starved for 2h in serum-free DMEM containing 2 mg/mL
glutamine, and then medium was replaced with serum-free DMEM containing vehicle or indicated inhibitor and incubated for 1h.
Then, cells were incubated in serum-free medium supplemented with 0.5mg/ml TMR-Dextran (Thermo Fisher Scientific) for
30 min. At the end of the incubation, cells were washed five times with 2ml ice-cold PBS and then immediately fixed in 3.7% para-
formaldehyde solution for 15 min. Cellular periphery was visualized with Alexa Fluor 488 Phalloidin (for F-actin staining) (Thermo
Fisher Scientific, 20 min incubation). For nuclear staining, cells were mounted with 100 mg/mL DAPI (Thermo Fisher Scientific) for
15 min. Coverslips were washed with 2ml PBS 3 times between each step. Z stack images were obtained with an Olympus confocal
FV1000 microscope using standard settings. Quantification of the macropinocytic index was done as previously described (Com-
misso et al., 2014). Mean fluorescence intensity was determined by calculating the integrated signal from randomly chosen fields
and normalized to the cell area determined by fluorescently labeled membrane markers (Alexa 488- Phalloidin for actin).
DQ-BSA Fluorescence Assay
After 2h starvation, serum-free DMEM medium was supplemented with 0.1 mg/mL DQ Red BSA (Molecular Probes) and cells incu-
bated for 4h and treated with either vehicle or 50 mMChloroquine (Sigma). For Figure 3I, Empty Vector KCPTEN cells were cultured in
5% EAAs ± 250nM Torin1 ± 3% BSA for 24 hours prior to the DQ-BSA assay. RICTOR-KO KCPTEN cells were cultured in 5% EAAs
without BSA. Cells were rinsed with ice-cold PBS and fixed with 3.7% paraformaldehyde for 15 min. Alexa Fluor-488 Phalloidin was
again used for F-actin and DAPI for nuclear visualization as described above and Z stack images were obtained with an Olympus
confocal FV1000 microscope using standard settings. Quantification was carried out as described above.
Western Blotting
Cells were plated at full DMEMmedium on 6-cm dishes and left overnight to adhere. Medium was changed as previously described
and cells were treated with the indicated concentrations of small-molecule inhibitors. Plates were placed on ice and cells were
washed 3x with ice-cold PBS. Whole-cell protein lysates were prepared in RIPA buffer (Thermo Fisher Scientific), containing 100x
Protease and Phosphatase inhibitors (Sigma), and total protein concentration was determined by DC protein assay (Bio-Rad). Pro-
teins were separated using precast 4%–12% or 3%–8%NuPAGE gels (Invitrogen, Life Technologies), and transferred onto nitrocel-
lulose membrane. Primary antibodies were used at 1:1000 dilution. Secondary antibodies were IRDye 800CW Donkey anti-Mouse
(Thermo Fisher Scientific), or Alexa Fluor 488 Goat anti-Rabbit (Invitrogen), all at 1:5000 dilution. Mouse monoclonal Anti-b-tubulinCell Reports 30, 2729–2742.e1–e4, February 25, 2020 e3
(Sigma) at 1:5000 was used as loading control. Proteins were detected and quantified using a Li-Cor Odyssey Infrared scanner and
software (Li-Cor Biosciences). ECLwas used for the development of membranes incubated with pAKT T308 antibody (Cell Signaling,
Cat#4056S).
Quantification of western blots was done using the Image Studio Lite.
QUANTIFICATION AND STATISTICAL ANALYSIS
Graphs were created, and statistical analysis was performed using GraphPad Prism 7.02 software. Statistical details can be found in
the figure legends.
DATA AND CODE AVAILABILITY
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